To address a precise view into molecular mechanisms of apoptotic signaling pathways after single-or combinatory treatments with specific NF-κB-or proteasome inhibitors and/or cisplatin (CDDP), flow cytometry and western blotting of the cell proteome in human ovarian chemosensitive-and CDDP-resistant cell lines were used. We report here that proteasome inhibition (but not NF-κB inhibition) caused marked alterations in the cell proliferation and cell cycle, as well as in the levels of signaling anti-and pro-apoptotic proteins PARP, NF-κB, IκB-α, Bcl-2, Bax, and lysosome-associated LAMP-1 and ATP-7B molecules in particular proteome fractions. These findings refer to the possibility of regulation of CDDP resistance, inclusive the capacity of lysosomes to export CDDP in certain human ovarian cancer cells by proteasome inhibition.
The development of CDDP resistance in diverse human cancer cells, inclusive ovarian cancer, often contributes to the therapeutic failure. Accumulating evidence suggests that anticancer drugs, inclusive CDDP, activate the nuclear transcription factor kappa B (NF-κB), a proinflammatory factor that has emerged as an important player in the development and progression of malignant cancers [1, 2] . NF-κB targets genes that promote tumor cell proliferation, survival, metastasis, inflammation, invasion, apoptosis and angiogenesis [3] and is relevant in the final response of normal and cancer cells to platinum drugs [4, 5] . Furthermore, NF-κB inhibition of activation and translocation sensitizes cancer cells to the effects of several anticancer compounds [6, 7] . Thus, combination of conventional chemotherapeutics with NF-κB inhibitors has been considered as an adjunct approach to sensitize cancer cells to chemotherapy [8, 9] .
The ubiquitin proteasome pathway represents the major catabolic pathway for intracellular protein degradation of short-lived and misfolded proteins including those involved in the cell cycle, apoptosis, transcription, DNA repair, protein quality control and antigen presentation [10] . Importantly, defects within this pathway are associated with a number of diseases, including cancer [11, 12] . At present accumulating evidence suggests that targeting the ubiquitin proteasome pathway by proteasome inhibitors leads to the inhibition of cell proliferation, alters the pathways leading to the NF-κB activation and subsequent translocation of this transcription factor to the nucleus to activate downstream pathways responsible for sensitization cancer cells to several anticancer agents [13, 14] .
Several dozens of proteins including pro-and antiapoptotic members of the Bcl-2 protein family have been shown to modulate the response to CDDP. Elevated levels of their antiapoptotic counterparts, including Bcl-2, Bcl-xl and Mcl-1 (myeloid cell leukemia sequence 1), correlate with CDDP resistance in different clinical scenarios, including head and neck cancer, ovarian cancer and NSCLC [15, 16] .
A great deal of attention was devoted to the two copper extruding P-type ATPases, ATP-7A and ATP-7B, as well as to the associated LAMP-1 and LAMP-2 proteins appeared to be upregulated in CDDP-resistant cancer cells [17, 18] . Notably, clinical studies indicate that ATP-7B expression levels might predict the sensitivity of ovarian and endometrial cancers to CDDP chemotherapy [19, 20] .
The aim of this study was in human ovarian carcinoma parental cells A2780 and their chemoresistant counterparts A2780/CP to examine cellular proteome responses after cell treatments with specific NF-κB-or proteasome inhibitors and in their individual combination with anticancer agent CDDP, respectively. We here report that in comparison with NF-κB inhibition, merely proteasome inhibition, or its combination with CDDP, correlated with effective inhibition of CDDP-resistance resulting in marked alterations in signaling/apoptotic survival pathways associated with exosomal pathways that participitate in CDDP export.
Materials and methods
Reagents. Propidium iodide (PI) and cisplatin (CDDP) were products of Sigma-Aldrich (St. Louis, MO, USA). NF-κB activating inhibitor (NF-κB-AI) and proteasome inhibitor I (PSI-I) were purchased from Calbiochem (San Diego, CA, USA). Fluoresceindiacetate (FDA) was a product of Molecular Probes (Eugene, Oregon, USA). Polyclonal antibodies against PARP, ATP-7B, mouse monoclonal antibody against LAMP-1, secondary HRP-IgGs and chemiluminiscence reagent (ECL) were purchased from Santa Cruz Biotechnology, Inc. (CA, USA). Polyclonal Bax, Bcl-2, Bcl-xL, NF-κB and IκB-α antibodies were obtained from Cell Signaling Technology, Inc. (MA, USA).
Cells and cytotoxicity assay. Human ovarian carcinoma cell line A2780 and its CDDP-resistant subline A2780/CP were obtained from ECACC (No. 93112519 and 93112517, respectively) and routinely cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 2 mM L-glutamine, 100 μg/ml penicillin and 50 μg/ml streptomycin, in 5% CO 2 humidified atmosphere, at 37 °C. For the experiments, approximately 0.5 x 10 6 cells/ml were cultivated individually with NF-κB-AI or PSI-I, and/or CDDP, with indicated doses (inhibitors were selectively added 3 hours prior to CDDP administration) in 96, 12 or 6 well plates (Greiner, Germany). Cytotoxicity of triplicates was measured after 48 hours and cell survival was determined by MTT assay [21] . Briefly, cells were plated at 1-2 x 10 3 cell density in 96-well culture plates, incubated with 50 μl of MTT (1 mg/ml) and left in the dark at 37 °C for an additional 4 hours. Finally, culture medium was removed, formazan crystals were dissolved in DMSO (200 μl) and the absorbance was measured at 540 nm and 690 nm in Microplate reader (Dynatech Lab Inc., Chantilly, VA, USA). The IC50 and combination indices (CI*) were determined by Calcusyn software (version 1.1, Biosoft).
Cell cycle analysis. Cell cycle determination was based on the cytometric measurements of the DNA content in nuclei labeled with propidium iodide (PI). Untreated or treated cells were kept in PBS containing 0.05% Triton X-100 and 15 μl RNA-se A (10 mg/ml) at 37 o C, for 20 min. Further, the cells were cooled and incubated on ice for 10 minutes and then PI (50 μg/ml) was added. Finally, the stained cells were analyzed using Beckman FACS Canto II flow cytometer [22] . Cell cycle was analysed with MultiCycle AV Plug-in to FCS Express version 3 software, Los Angeles, CA, USA.
Flow cytometric analysis of apoptosis. Apoptotic cell enumeration was evaluated by the amount of cells with the cell membrane impermeable for PI and decreased amount of fluorescein [23] . Approximately 5 x 10 5 untreated or treated cells were resuspended in 400 μl of PBS/0.2% BSA containing 10 nM of FDA at room temperature, for 30 min. Then the cells were cooled, incubated with 4 μl of PI (1 mg/ml) for 15 min on ice and measured using Beckman FACS Canto II flow cytometer. Data were analysed with FCS Express version 3, De Novo Software, Los Angeles, CA, USA.
Cell proteome fractions and western blot analysis. To study subcellular proteomes we used fast and reproducible extraction executed by the ProteoExtract® Subcellular Proteome Extraction Kit (S-PEK, Calbiochem, USA). Cultured cells (5 x 10 6 ) were washed in PBS and lysed in S-PEK buffered lysis system containing phosphatase inhibitors (2 mM sodium orthovanadate, 2 mM sodium fluoride) and then we worked according to the procedure recommended by the provider. Equal portions of protein lysates (10 μl for each of F1 -F4 fractions) were run in 12.5 % SDS/PAGE gels, transferred to nitrocellulose membrane and incubated with corresponding polyclonal/monoclonal IgGs. The protein-antibody complexes were detected using secondary HRP-IgGs followed by enhanced chemiluminescence reagent (ECL).
Results

MTT assay and combination indices (CI*).
In all experiments the two inhibitors were used: NF-κB specific activation inhibitor, NF-κB-AI (a highly potent inhibitor of NF-κB transcriptional activation) and proteasome inhibitor I, PSI-I (reversible proteasome inhibitor with chymotrypsinlike activity of the multicatalytic proteinase complex of 20S proteasome). To assess the effects of NF-κB-AI, PSI-I, and/or CDDP, chemosensitive (A2780) and CDDP-resistant (A2780/CP) human ovarian cancer cells were processed with the drugs in dose dependent manner (Fig. 1) . Unexpectedly, 0.1 -5 μM and even higher (> 5 μM, data not shown) doses of NF-κB-AI had minimal effect on the viability of both cell variants. By contrast, nanomolar concentrations of PSI-I exerted effective inhibition of cell proliferation of the studied cell sublines. Calculating from MTT assay and CI* (Tab. 1), drug concentrations for further experiments were fixed at 0.5 μM (NF-κB-AI) or 20 nM (PSI-I) for both cell variants, and 10 μM CDDP for sensitive-, and 25 μM CDDP for resistant cells, respectively. The obtained results showed that administration of NF-κB-AI rendered only slight effect on CDDP activity (CI*~1) in the studied cell variants, while co-treatment with PSI-I and CDDP induced synergistic effect (CI* < 1) in these sublines.
Flow cytometry of the cell cycle and apoptosis. In both cell variants, long-term (48 hours) treatments with NF-κB-AI or PS-I and/or CDDP induced diverse cell cycle alterations. Single CDDP induced predominantly S-phase arrest in these cells. Unexpectedly, single NF-κB-AI had no effect on the cell cycle course of the studied cells, whereas PS-I administration accumulated both cell subtypes in S and G2/M cell cycle phases. Of interest, while NF-κB-AI exerted no significant effect on the cell cycle of CDDP treated cells, co-treatment with PS-I and CDDP partially reduced the cell number in S phase with increased G2/M phase (Fig. 2 A) .
To evaluate apoptotic events due to drug treatments, FDA/ PI staining and cytometric measurements were executed. , where the later, in comparison with untreated cells, was almost equally distributed in both F2 and F3 subcellular compartments. Interestingly, NF-κB expression levels (constitutively upregulated in resistant cells) linked to nuclear fraction (F3), due to apoptotic events were markedly reduced in F3, and this was accompanied by IκB-α downregulation in cytosolic compartment (F1). Furthermore, western blots showed that the membrane/organelle protein fraction (F2) from chemosensitive cells comprised much higher constitutive amounts of lysosomal LAMP-1 and ATP-7B protein levels then those found in chemoresistant counterparts. Notably, apoptotic events induced by PSI-I and/or CDDP correlated the processes such as cell differentiation or drug resistance regulation.
To gain a deeper insight into molecular mechanism(s) of a complex intracellular apoptosis signaling network that ultimately regulates gene expression in response to NF-κB-AI or PS-I and/or CDDP, we used western blotting to analyse particular subcellular proteomes (Fig. 3) . Of note, after the treatments with NF-κB-AI no substantial changes in signaling pro-and anti-apoptotic molecules PARP, NF-κB, I-κBα, Bcl-2, Bax and lysosomal LAMP-1 and ATP-7B were determined in both sublines examined. On the other hand, marked alterations in these molecules distributed in proper cell proteome fractions were found after proteasome inhibition with PSI-I or its combination with CDDP. Apoptotic events induced by PS-I and/or CDDP were indicated in both cell variants as in chemoresistant cells with elevated levels of LAMP-1 and ATP-7B molecules.
Discussion
Several anticancer drugs, including platinum compounds, have been reported to induce NF-κB activation in diverse cancer cells [24] [25] [26] . Activation of NF-κB contributes to aggressive tumor growth and also to chemotherapy resistance, and, on the other hand, NF-κB inactivation mediates decreased activity of anti-apoptotic-and increased upregulation of apoptotic genes [27, 28] . In line with this fact, in recent years much effort has been invested in developing NF-κB-blocking agents, including CDDP, natural compounds and their semisynthetic or synthetic analogues [29] [30] [31] .
The ubiquitin-proteasome pathway plays an important role in NF-κB regulation of the cell cycle, tumor growth, and metastasis [32, 33] . Therefore, proteasome inhibitors have been developed to inhibit tumor growth and angiogenesis and their efficacy was vigorously investigated mainly in hematological malignancies [34, 35] . Recently, chemosensitizing activity of proteasome inhibitor bortezomib (PS 341) has ben well documented in the treatment of multiple myeloma, and this may be due, at least in part, to the inhibition of NF-κB [36, 37] .
In order to find the relationship between NF-κB transcriptional and proteasomal activity, in relation to combination therapy with CDDP, some events associated with the cell growth, cell cycle and the expression of apoptotic cell portions in chemosensitive-and chemoresistant human ovarian cancer cell lines were evaluated. For this aim we used a cell-permeable highly potent inhibitor of NF-κB transcriptional activation (NF-κB-AI) and reversible proteasome inhibitor I (PS-I) with chymotrypsin-like activity. Here we provide evidence that, in contrast with NF-κB inhibition, intervention in the proteasome resulted in reduced cell growth, cell cycle arrest and markedly enhanced numbers of apoptotic cells. Moreover, combination treatments executed with PSI-I and CDDP showed synergy to induce apoptotic events not only in parental but also in chemoresistant subline.
To confirm these observations we analyzed for the first time subcellular proteomes obtained with the aid of proteome extraction buffer system. This technique allowed us in four cell fractions to determine distinct protein molecules and study their possible translocation due to alterations in cell signaling/apototic events, as a result of potential CDDP resistance modulation. The experiments revealed that specific NF-κB-AI exerted no substantial efficacy of inhibition CDDP resistance monitored by western blots of the pro-and anti-apoptoticassociated proteins PARP, NF-κB, IκB-α, Bcl-2, and Bax. In contrast to NF-κB-AI activity, cell proteome lysates prepared from the cells treated with PSI-I revealed increased portion of apoptotic cells in both cell variants and these were increased by combined administration of PS-I and CDDP. These events led to PARP cleavage in nuclear fraction (F3), NF-κB (constitutively upregulated in resistant cells) decrease in cytosolic (F1)-, membrane/organelle (F2) fractions, as well as in nuclear fraction (F3), accompanied by downregulation of IκB-α in cytosolic fraction (F1). This refers to the fact of blocked NF-κB transport to the nucleus, its accumulation and subsequent degradation in cytoplasm followed by blocked IκB-α transport to proteasome and its intracellular degradation. Apoptotic events also led to both Bcl-2 decrease and enhanced Bax levels in F2. Similar results we obtained by the use of another proteasome inhibitor, naturally occurring triterpenoid pristimerin (data not shown). These observations are in relation with those determined in CDDP-resistant HL60/B cells with higher levels of NF-κB50 and NF-κB65, where the block of IκB degradation by the proteasome inhibitor PS-I induced cell death [38] . Furthermore, in combination with some conventional chemotherapeutics, proteasome inhibitors including PSI-I, lactacystin and bortezomib increased their cytotoxic activity accompanied by the decrease of several anti-apototic molecules or enhanced apoptotic activity in diverse human cancer cells [39, 40] . Further, accumulating evidence suggests that overexpression of antiapoptotic members of the Bcl-2 protein family, Bcl-2, Bcl-xl and MCL-1 confers resistance to several stressors in vitro. In this context, ongoing clinical trials are evaluating the combination of CDDP with small molecules that inhibit Bcl-2-like proteins (for example, ABT-263, ABT-737) for the treatment of several neoplasms [15, 16, 39] . On the other hand, it has been referred that deficiency of Bax/Bak-proapoptotic members of the Bcl-2 protein family confers resistance to several compounds inclusive CDDP [41, 42] .
It was further of particular interest to find if the levels of lysosomal associated protein LAMP-1 and ATP-7B in the studied cells were modified by NF-κB-or proteasome inhibition. As showed western blots, administered NF-κB-AI inhibitor exerted no significant effect upon these protein levels found in membrane-organelle fractions (F2) in both cells sublines. Intriguingly, apoptotic events induced by PSI-I inhibition or its combination with CDDP, led to marked enhancement of these lysosomal molecules in chemoresistant cells that could point to a worsened transport of CDDP out of the resistant cells. The link between CDDP-resistant phenotype and lysosomal/exosomal CDDP export would be based on the fact of the sequestration of CDDP into lysosomes associated with ATP-7A and ATP-7B copper transporters, multidrug resistant protein transporter MRP2 (ABCB2), as well as with LAMP-1 and LAMP-2 proteins [17] [18] [19] [20] .
The obtained results justify us to assume that inhibiton of NF-κB transcriptional activation, i.e. blocking the interaction between RNA polymerase and a particular DNA promoter may not be sufficient to modulate/reverse CDDP resistance in studied ovarian CDDP-resistant cells monitored by the appearance of apoptosis. By contrast, proteasome inhibition, at least that exerted by the chymotrypsin-like activity of the multicatalytic proteinase complex of 20S proteasome, appeared as effective to stimulate apoptotic pathways which were potentiated by CDDP. Therefore, the relevancy of the expression status, transcriptional activity and nuclear translocation of NF-κB upon apoptosis needs to be carefully interpreted in diverse experimental cell systems. Thus, here presentend results indicate the possibility to circumvent CDDP resistance by proteasome inhibition and the capacity of combination therapy with specific proteasomal inhibitors and chemotherapeuticals that might be exploited for reverting CDDP resistance in human tumors.
